Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
M.D. Anderson Cancer Center
With
OBJECTIVES: * Determine the clinical activity of imatinib mesylate (STI571) in patients with metastatic melanoma. * Determine the side effects of this drug in these patients. * Correlate molecular studies with responsiveness to this drug in these patients. OUTLINE: Patients receive oral imatinib mesylate (STI571) twice daily. Treatment continues in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 21-78 patients will be accrued for this study within 6-15 months.
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted